NEW YORK (GenomeWeb) – Alere announced this week that it will initiate a voluntary withdrawal of its anti-coagulation monitoring INRatio and INRatio2 PT/INR Monitoring System. The company said it is working with the US Food and Drug Administration to determine the most appropriate timing to discontinue the product, and will provide guidance on transitioning patients to an alternate product.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.